Medivation shares are soaring on positive test results. But investors may be getting ahead of reality here.

The post Overreacting to a Prostate Cancer Drug? appeared first on InvestorPlace.

FDA approval of Bydureon -- a once-a-week injectable drug -- could make Amylin a takeover target for a Big Pharma.

The post Amylin Gets a Boost From Its Diabetes Drug Approval appeared first on InvestorPlace.

That's where a slew of info-tech companies, ranging from giant Oracle to tiny BioClinica, come in. However, investing is them is no slam dunk.

The post Someone Has to Crunch All That Clinical Trial Data appeared first on InvestorPlace.

Companies like BioMarin Pharmaceutical are cashing in on rare diseases, where they can charge hundreds of thousands of dollars every year for their drugs.

The post Small Patient Population? Charge $400K a Year for Your Drug appeared first on InvestorPlace.

Swiss health care giant Roche made a hostile bid to buy Illumina for $44.50 per share, but many think that number will be higher when all is said and done.

The post Roche’s Hostile Bid for Illumina Could Reach $60 Per Share appeared first on InvestorPlace.

Controversial British researcher touting use of "magic mushroom" compound psilocybin in treating depression as illegal drugs move further into pharma forefront.

The post Do Magic Mushrooms Hold the Key to Treating Depression? appeared first on InvestorPlace.

After the deaths of 11 people who were taking the drug, concerns that Gilenya may cause heart problems has hit NVS hard, ending the stock's months-long upswing.

The post If Novartis’ MS Drug Falters, Biogen Will Gain appeared first on InvestorPlace.

Small and midsize drugmakers are where the action is -- in both research and M&A activity. For healthy dividends, however, Big Pharma still rules.

The post The Little Guys Are Pharma’s New Stars appeared first on InvestorPlace.

Connecticut recently dropped private insurers from serving its Medicaid members, but many of the industry's big names are far from worried.

The post Despite Connecticut Change on Medicaid, Outlook Strong for Health Insurers appeared first on InvestorPlace.

You bet they are: Patent losses, a higher bar for FDA approvals, and slew of smaller, nimbler rivals have reshaped the industry.

The post Are Pharma’s ‘Good Old Days’ Gone Forever? appeared first on InvestorPlace.

The pharma giant says it's determined to be the leader in treatments for the disease -- a market that is expected to hit $20 billion by 2020.

The post Merck Is Shopping for Smarts In Hep C appeared first on InvestorPlace.

Their hepatitis C drugs could be lures for Big Pharma after a rival gets a juicy offer from Bristol-Myers Squibb.

The post Idenix and Achillion Jump on Takeover Talk appeared first on InvestorPlace.

Despite dropping by more than 10% since October, Stericycle shares still have more room below it. But the company does have a few options to reassure investors.

The post Why Disposing of Stericycle Shares May Be Right Move appeared first on InvestorPlace.

Dendreon saw its stock jump Thursday as sales of its cancer drug beat the expectations of both analysts and the company itself.

The post Dendreon Jumps 40% on Provenge Sales appeared first on InvestorPlace.

Drug industry vet Jeremy Levin earned his stripes making deals for Bristol-Myers Squibb, but he'll face tough going at the generic-drug maker.

The post Teva’s New CEO Is Battle-Tested. Good Thing appeared first on InvestorPlace.

Mead Johnson's recent Enfamil scare sent many investors packing -- but those who stuck with the stock could soon be rewarded.

The post Mead Johnson Bounce Followed J&J Script appeared first on InvestorPlace.

Pressure on pharmaceutical companies for evidence that their drugs work is fueling a surge in the global market for "companion diagnostics."

The post FDA, Insurers Demand Tests for New Drugs appeared first on InvestorPlace.

Barry Cohen discusses some of his picks from 2011 -- and how that will affect his take on companies moving forward.

The post 2011’s Best and Worst Picks From InvestorPlace’s Barry Cohen appeared first on InvestorPlace.

CVS says it could gobble up to 23M prescriptions that Walgreens has sold through Express Scripts if a deal isn't announced. So far, WAG is sticking to its guns.

The post Walgreen Not Sweating Loss of Express Scripts Customers to CVS — Should It Be? appeared first on InvestorPlace.

Ariad Pharmaceuticals is up 120% in the past 12 months, mostly fueled on optimism over its trial leukemia treatment. But some analysts think the ceiling is higher.

The post Ariad Pharmaceuticals Still Might Have Upside appeared first on InvestorPlace.

After a decade as CEO, the oft-maligned Kevin Sharer will step down. That's giving shareholders holiday cheer as they bid the stock up on the news.

The post Amgen CEO Says ‘I’m Leaving.’ Investors Say ‘Good Riddance’ appeared first on InvestorPlace.

The experimental cancer drug Johnson & Johnson bought last week is receiving high praise, and could be "paradigm-shifting."

The post Researcher: J&J/Pharmacyclics Drug Could Be a Game-Changer appeared first on InvestorPlace.

Could Sanofi, Novartis or GlaxoSmithKline be next to separate pharmaceutical development into a stand-alone company?

The post Covidien Follows Abbott With a Pharma Spin-Off appeared first on InvestorPlace.

The company brings holiday cheer with its new stock repurchase program and dividend boost.

The post Pfizer Delivers Early Holiday Gifts to Shareholders appeared first on InvestorPlace.

Shareholders would likely be better served by the company's prescription drug business standing alone. Here's why.

The post Abbott Labs Spinoff Looks Like the Right Move appeared first on InvestorPlace.

Shares have surged as the company continues to be the dominant player in a fast-growing health care sector.

The post Intuitive Surgical Shares Are In the Pink appeared first on InvestorPlace.

If Eli Lilly is successful in delaying the progression of Alzheimer’s disease with its experimental drug, it could make Lipitor look like a mid-sized product. The odds?

The post Why Eli Lilly Could Be a Lottery Stock Pick appeared first on InvestorPlace.

Affymax's stock price is swinging wildly as investors await a ruling on the company's promising kidney disease drug.

The post Affymax Shares Hang on an FDA Decision appeared first on InvestorPlace.

The high-risk generic drug sector still is without an ETF, leaving investors to weed out the pharmaceutical winners and losers for themselves.

The post Investors Still Must Pick Generic Drug Companies By Hand appeared first on InvestorPlace.

UnitedHealth's latest deal is a deft move toward profiting off the growing number of retiring baby boomers.

The post Growing Medicare Patient Base Could Restore Luster to UnitedHealth Shares appeared first on InvestorPlace.

The company's current and future drugs are likely attractive to larger companies faced with slowing growth.

The post Onyx Pharma May See Suitors Lining Up appeared first on InvestorPlace.

Ranbaxy could sell $650 million worth of the drug in its first 180 days. But Pfizer is battling hard to keep branded Lipitor alive.

The post Ranbaxy Closes In on FDA Approval for Generic Lipitor appeared first on InvestorPlace.

The major pharmaceutical companies are hoping to supply the definitive treatments, but the medical community hasn't yet declared a winner.

The post Blood-Thinner Drug Race Is Still Wide Open appeared first on InvestorPlace.

Merck CEO Kenneth Frazier acknowledges company's lagging stock, touts potential of numerous drugs in late development stages.

The post Merck CEO Pledges Drug Pipeline Will Yield Results in Both Short and Long Term appeared first on InvestorPlace.

Like a vampire refusing to die, Lipitor keeps on going. Now, PFE has a deal to sell the cholesterol-lowering drug directly to patients at generic cost.

The post Pfizer’s Latest Gambit for Keeping Lipitor Alive appeared first on InvestorPlace.

The $11B price tag raises the stakes big-time, and critics say Gilead is overpaying to get Pharmasset's promising hepatitis C treatment.

The post Gilead’s Giant Gamble in Buying Pharmasset appeared first on InvestorPlace.

These companies are making progress on new therapeutic cancer vaccines -- and success for any one of them could be huge for investors.

The post Stocks to Watch on Cancer Vaccines’ Huge Financial Potential appeared first on InvestorPlace.

Companies are finding plans for global expansion aren't without hiccups.

The post Big Pharma’s Emerging Markets Foray Hits Roadblocks appeared first on InvestorPlace.

Cleveland Clinic's positive review revitalizes Bristol-Myers, AstraZeneca's dapagliflozin, an experimental drug taking on a growing diabetes management market.

The post Bristol-Myers, AstraZeneca Diabetes Drug Gets New Hope appeared first on InvestorPlace.

French drug giant Sanofi (SNY) is counting on mergers and acquisitions to restore profit growth amid a slew of patent expirations.

The post Sanofi Relies on Shopping to Offset Patent Losses on Key Drugs appeared first on InvestorPlace.

Efforts to preserve the lucrative cholesterol-drug's franchise have sparked an antitrust suit. But competition is inevitable.

The post Pfizer Pushes to Keep Lipitor Profits Flowing appeared first on InvestorPlace.

As Eli Lilly looks elsewhere for a diabetes drug partner, Amylin Pharmaceuticals stumbles. But Lilly is happy as can be. Here's why.

The post Amylin Stumbles After Lilly Pulls Partnership Plug appeared first on InvestorPlace.

With their hepatitis C drugs showing promise in trials, these drug makers have become attractive targets for bigger pharma players.

The post Hepatitis C Drug Progress Puts Several Companies on Acquisition Watch appeared first on InvestorPlace.

Medivation (MDVN) gains almost 140% Thursday on encouraging results for its prostate cancer treatment, and Dendreon (DNDN) is further battered.

The post Medivation Shares Shoot Up on Prostate Cancer Treatment News appeared first on InvestorPlace.

Dendreon (DNDN) appears to be pulling out all the stops in an effort to restore at least some of the luster to its prostate cancer treatment Provenge.

The post Why Dendreon Is Aiming Prostate Drug Pitches to Consumers appeared first on InvestorPlace.

Amgen's (AMGN) third-quarter earnings, budget management and full-year outlook turn positive, boosting the company's market prospects.

The post Amgen Bids for a Return to Favor appeared first on InvestorPlace.

Big-name med-tech companies are looking to branch out in a $300 billion market. Here are five potential targets that could be swallowed up soon.

The post 5 Potential Acquisition Targets in Medical Device Stocks appeared first on InvestorPlace.

Smaller insurers are catching attention in the wake of expected consolidation.

The post Cigna Deal Signals More Insurance Buyouts to Come appeared first on InvestorPlace.

Amgen (Nasdaq:AMGN) is among several pharmaceutical companies working on a treatment for pancreatic cancer, the deadly disease that recently felled both Steve Jobs of Apple (Nasdaq:AAPL) and Nobel Prize-winning immunology expert Ralph Steinman. Amgen is partnered with Japan’s Takeda on development of a drug called ganitumab, which is a monoclonal antibody designed to block a…

The post Amgen Leads Firms In Pancreatic Cancer Drug Chase appeared first on InvestorPlace.

Abbott's Humira is a dollar-printing temptation for several companies, but Pfizer's tofacitinib could change the rheumatoid arthritis drug landscape.

The post Big Pharma Might Already Have Sights on Abbott Spinoff appeared first on InvestorPlace.